User login
Along with a strong focus on peripheral arterial disease, VIVA late-breaking clinical trial reports will also address other critical areas of the vascular domain, from the aorta to the carotids.
On Tuesday morning, the results of two trials will be presented, which are investigating endovascular aortic repair. Ali Azizzadeh, MD, Memorial Hermann Heart and Vascular Institute, Houston, will discuss the 3-year results from the Valiant IDE Study, examining endovascular repair in acute, complicated type B aortic dissection.
Then, Zvonimir Krajcer, MD, Texas Heart Institute, Houston, will present the final results from the Prospective LIFE Registry, looking at fast-track endovascular aortic repair.
Also on Tuesday morning, the issue of interventions after the creation of an arteriovenous fistula (AVF) will be addressed by Charmaine Lok, MD, Toronto General Hospital, comparing traditional surgical AVF creation with a new endovascular approach.
Wednesday morning, Ido Weinberg, MD, Massachusetts General Hospital, Boston, will address the issue of carotid stent fractures, demonstrating that they are not associated with restenosis, stroke, myocardial infarction, or death based on the results from the ACT 1 Multicenter Randomized Trial.
Along with a strong focus on peripheral arterial disease, VIVA late-breaking clinical trial reports will also address other critical areas of the vascular domain, from the aorta to the carotids.
On Tuesday morning, the results of two trials will be presented, which are investigating endovascular aortic repair. Ali Azizzadeh, MD, Memorial Hermann Heart and Vascular Institute, Houston, will discuss the 3-year results from the Valiant IDE Study, examining endovascular repair in acute, complicated type B aortic dissection.
Then, Zvonimir Krajcer, MD, Texas Heart Institute, Houston, will present the final results from the Prospective LIFE Registry, looking at fast-track endovascular aortic repair.
Also on Tuesday morning, the issue of interventions after the creation of an arteriovenous fistula (AVF) will be addressed by Charmaine Lok, MD, Toronto General Hospital, comparing traditional surgical AVF creation with a new endovascular approach.
Wednesday morning, Ido Weinberg, MD, Massachusetts General Hospital, Boston, will address the issue of carotid stent fractures, demonstrating that they are not associated with restenosis, stroke, myocardial infarction, or death based on the results from the ACT 1 Multicenter Randomized Trial.
Along with a strong focus on peripheral arterial disease, VIVA late-breaking clinical trial reports will also address other critical areas of the vascular domain, from the aorta to the carotids.
On Tuesday morning, the results of two trials will be presented, which are investigating endovascular aortic repair. Ali Azizzadeh, MD, Memorial Hermann Heart and Vascular Institute, Houston, will discuss the 3-year results from the Valiant IDE Study, examining endovascular repair in acute, complicated type B aortic dissection.
Then, Zvonimir Krajcer, MD, Texas Heart Institute, Houston, will present the final results from the Prospective LIFE Registry, looking at fast-track endovascular aortic repair.
Also on Tuesday morning, the issue of interventions after the creation of an arteriovenous fistula (AVF) will be addressed by Charmaine Lok, MD, Toronto General Hospital, comparing traditional surgical AVF creation with a new endovascular approach.
Wednesday morning, Ido Weinberg, MD, Massachusetts General Hospital, Boston, will address the issue of carotid stent fractures, demonstrating that they are not associated with restenosis, stroke, myocardial infarction, or death based on the results from the ACT 1 Multicenter Randomized Trial.
